Organ-Specific, Fibroblast-Derived Matrix as a Tool for Studying Breast Cancer Metastasis

• Main Authors: Adina R. D. Jensen, Edward R. Horton, Lene H. Blicher, Elin J. Pietras, Cornelia Steinhauer, Raphael Reuten, Erwin M. Schoof, Janine T. Erler
• Format: Article
• Language: English
• Published: MDPI AG 2021-07-01
• Series: Cancers
• Subjects: fibroblast-derived matrix; cancer; drug screening
• Online Access: https://www.mdpi.com/2072-6694/13/13/3331

During the metastatic process, breast cancer cells must come into contact with the extra-cellular matrix (ECM) at every step. The ECM provides both structural support and biochemical cues, and cell–ECM interactions can lead to changes in drug response. Here, we used fibroblast-derived ECM (FDM) to perform high throughput drug screening of 4T1 breast cancer cells on metastatic organ ECM (lung), and we see that drug response differs from treatment on plastic. The FDMs that we can produce from different organs are abundant in and contains a complex mixture of ECM proteins. We also show differences in ECM composition between the primary site and secondary organ sites. Furthermore, we show that global kinase signalling of 4T1 cells on the ECM is relatively unchanged between organs, while changes in signalling compared to plastic are significant. Our study highlights the importance of context when testing drug response in vitro, showing that consideration of the ECM is critically important.